Back to search

Peptide record

TPDB12249

RP9 Antibacterial Anticancer Toxicity standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB12249
RP9
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0 dbACP ToxinPred 3.0
standard
No
A 9-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
RGSALTHLP
Physicochemical Analysis
C41H70N14O12
NDCEQIKMFWYV
L
951.09
11.05
2
0
3
+1
1.21
-0.200
97.78
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
2
Residue Composition
number
1
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
1
H
0
I
2
L
0
K
0
M
0
F
1
P
1
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 0 L: 2 K: 0 M: 0 F: 0 P: 1 S: 1 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C41H70N14O12
951.09
11.05
+1
1.21
-0.200
Free
L
Linear
Free
Antimicrobial and Anticancer
Crocodylus siamensis
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
61.2 µM

Target

B. pumilus

Source & Reference

NA

Other

Active against Gram-negative V. cholerae and Gram-positive B. pumilus (MIC 61.2 uM). Weak anticancer activity (IC50s are 126 uM to HeLa cells and 168 uM to CaSki cells).
Evidence 2 Activity

Activity

IC50
IC50 = 126.24 ± 3.5 µM
Anticancer
126.24

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

Sulforhodamine B assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2016

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 3 Activity

Activity

IC50
IC50 = 168.33 ± 1.6 µM
Anticancer
168.33

Target

Cervical Cancer
CaSki
Cervix

Assay & Model

Sulforhodamine B assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2016
Evidence 4 Activity

Activity

3% Hemolysis
Toxicity
61.2 µM
Hemolytic Cytotoxic
3% Hemolysis | 61.2 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cationic Antimicrobial Peptides Derived from Crocodylus siamensis Leukocyte Extract, Revealing Anticancer Activity and Apoptotic Induction on Human Cervical Cancer Cells. | Protein J | 2016
Evidence 5 Activity

Activity

6% Hemolysis
Toxicity
122.4 µM
Hemolytic Cytotoxic
6% Hemolysis | 122.4 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cationic Antimicrobial Peptides Derived from Crocodylus siamensis Leukocyte Extract, Revealing Anticancer Activity and Apoptotic Induction on Human Cervical Cancer Cells. | Protein J | 2016
Evidence 6 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Cationic Antimicrobial Peptides Derived from Crocodylus siamensis Leukocyte Extract, Revealing Anticancer Activity and Apoptotic Induction on Human Cervical Cancer Cells. | Protein J | 2016
Evidence 7 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Protein J. 2016 Jun 35(3):202-11.